会員登録
ログイン
【4570】免疫生物研究所
研究用試薬。
類似企業：
【業界1位】
小野薬品工業
【業界1位】
小野薬品工業
売上高
営業利益
経常利益
当期利益
業績予想修正
対前回修正率
当初予想比較
| 決算期 | 日付 | 予・実 | 売上高 (百万円) | 対前回 | 営業利益 (百万円) | 対前回 | 経常利益 (百万円) | 対前回 | 当期利益 (百万円) | 対前回 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025.03 | 2025/02/18 | 修正予 | 925 | → | 180 | ↑ | 180 | ↑ | 215 | ↑ |
| 2025.03 | 2025/02/10 | Q3予 | 925 | → | 120 | → | 120 | → | 115 | → |
| 2025.03 | 2024/11/11 | Q2予 | 925 | → | 120 | → | 120 | → | 115 | → |
| 2025.03 | 2024/08/08 | Q1予 | 925 | → | 120 | → | 120 | → | 115 | → |
| 2025.03 | 2024/05/14 | 当初予 | 925 | - | 120 | - | 120 | - | 115 | - |
| 2024.03 | 2024/05/14 | 実 | 816 | → | 104 | → | 125 | → | 186 | → |
| 2024.03 | 2024/05/10 | 修正予 | 816 | ↓ | 104 | ↑ | 125 | ↑ | 186 | ↑ |
| 2024.03 | 2024/02/02 | Q3予 | 850 | → | 90 | → | 90 | → | 80 | → |
| 2024.03 | 2023/11/02 | Q2予 | 850 | → | 90 | → | 90 | → | 80 | → |
| 2024.03 | 2023/08/07 | Q1予 | 850 | → | 90 | → | 90 | → | 80 | → |
| 2024.03 | 2023/05/12 | 当初予 | 850 | - | 90 | - | 90 | - | 80 | - |
| 2023.03 | 2023/05/12 | 実 | 794 | → | 58 | → | -149 | ↓ | -289 | → |
| 2023.03 | 2023/04/27 | 修正予 | 794 | ↑ | 58 | ↑ | -127 | ↓ | -289 | ↓ |
| 2023.03 | 2023/02/06 | Q3予 | 775 | → | 3 | → | -95 | → | -120 | → |
| 2023.03 | 2022/11/04 | Q2予 | 775 | → | 3 | → | -95 | → | -120 | → |
| 2023.03 | 2022/08/05 | Q1予 | 775 | → | 3 | → | -95 | → | -120 | → |
| 2023.03 | 2022/05/13 | 当初予 | 775 | - | 3 | - | -95 | - | -120 | - |
| 2022.03 | 2022/05/13 | 実 | 647 | ↑ | -122 | ↑ | -243 | ↑ | -258 | ↓ |
| 2022.03 | 2022/03/15 | 修正予 | 645 | ↓ | -128 | ↓ | -246 | ↓ | -255 | ↓ |
| 2022.03 | 2022/02/04 | Q3予 | 770 | → | -107 | → | -154 | → | -162 | → |
| 2022.03 | 2021/11/05 | Q2予 | 770 | → | -107 | → | -154 | → | -162 | → |
| 2022.03 | 2021/08/06 | Q1予 | 770 | → | -107 | → | -154 | → | -162 | → |
| 2022.03 | 2021/05/14 | 当初予 | 770 | - | -107 | - | -154 | - | -162 | - |
| 2021.03 | 2021/05/14 | 実 | 602 | ↑ | -240 | ↑ | -310 | ↑ | -318 | ↑ |
| 2021.03 | 2021/02/12 | Q3予 | 549 | → | -308 | → | -410 | → | -430 | → |
| 2021.03 | 2020/11/06 | Q2予 | 549 | → | -308 | → | -410 | → | -430 | → |
| 2021.03 | 2020/08/07 | Q1予 | 549 | → | -308 | → | -410 | → | -430 | → |
| 2021.03 | 2020/08/06 | 当初予 | 549 | - | -308 | - | -410 | - | -430 | - |
| 2020.03 | 2020/05/14 | 実 | 576 | ↑ | -595 | ↑ | -678 | ↑ | -668 | ↑ |
| 2020.03 | 2020/03/17 | 修正予 | 565 | ↓ | -650 | ↓ | -730 | ↓ | -745 | ↓ |
| 2020.03 | 2020/02/07 | Q3予 | 670 | → | -510 | → | -640 | → | -655 | → |
| 2020.03 | 2019/11/08 | Q2予 | 670 | ↓ | -510 | ↓ | -640 | ↓ | -655 | ↓ |
| 2020.03 | 2019/08/02 | Q1予 | 991 | → | -391 | → | -550 | → | -565 | → |
| 2020.03 | 2019/05/14 | 当初予 | 991 | - | -391 | - | -550 | - | -565 | - |
| 2019.03 | 2019/05/14 | 実 | 781 | ↑ | -173 | ↓ | -155 | ↓ | -167 | ↓ |
| 2019.03 | 2019/03/22 | 修正予 | 780 | ↓ | -150 | ↓ | -134 | ↓ | -150 | ↓ |
| 2019.03 | 2019/02/01 | Q3予 | 982 | → | -25 | → | -24 | → | -39 | → |
| 2019.03 | 2018/11/05 | Q2予 | 982 | → | -25 | → | -24 | → | -39 | → |
| 2019.03 | 2018/08/03 | Q1予 | 982 | → | -25 | → | -24 | → | -39 | → |
| 2019.03 | 2018/05/14 | 当初予 | 982 | - | -25 | - | -24 | - | -39 | - |
| 2018.03 | 2018/05/14 | 実 | 758 | ↑ | -48 | ↑ | -49 | ↑ | -52 | ↑ |
| 2018.03 | 2018/03/16 | 修正予 | 745 | ↓ | -70 | ↑ | -75 | ↑ | -78 | ↑ |
| 2018.03 | 2018/02/02 | Q3予 | 773 | → | -116 | → | -122 | → | -128 | → |
| 2018.03 | 2017/11/02 | Q2予 | 773 | → | -116 | → | -122 | → | -128 | → |
| 2018.03 | 2017/08/04 | Q1予 | 773 | → | -116 | → | -122 | → | -128 | → |
| 2018.03 | 2017/05/12 | 当初予 | 773 | - | -116 | - | -122 | - | -128 | - |
| 2017.03 | 2017/05/12 | 実 | 741 | → | -1,156 | → | -1,170 | → | -2,094 | → |
| 2017.03 | 2017/05/10 | 修正予 | 741 | ↓ | -1,156 | ↓ | -1,170 | ↓ | -2,094 | ↓ |
| 2017.03 | 2017/02/03 | Q3予 | 800 | → | -180 | → | -180 | → | -190 | → |
| 2017.03 | 2016/11/04 | Q2予 | 800 | → | -180 | → | -180 | → | -190 | → |
| 2017.03 | 2016/08/04 | Q1予 | 800 | → | -180 | → | -180 | → | -190 | → |
| 2017.03 | 2016/05/13 | 当初予 | 800 | - | -180 | - | -180 | - | -190 | - |
| 2016.03 | 2016/05/13 | 実 | 717 | → | -75 | → | -81 | → | -31 | → |
| 2016.03 | 2016/05/09 | 修正予 | 717 | ↓ | -75 | ↑ | -81 | ↑ | -31 | ↑ |
| 2016.03 | 2016/02/05 | Q3予 | 730 | → | -115 | → | -120 | → | -55 | → |
| 2016.03 | 2015/11/06 | Q2予 | 730 | ↓ | -115 | ↓ | -120 | ↓ | -55 | ↓ |
| 2016.03 | 2015/08/04 | Q1予 | 900 | → | -35 | - | -50 | → | 20 | → |
| 2016.03 | 2015/05/13 | 当初予 | 900 | - | - | - | -50 | - | 20 | - |
| 2015.03 | 2015/05/13 | 実 | - | - | - | - | - | - | - | - |
| 2015.03 | 2015/02/06 | Q3予 | 700 | → | -170 | → | -140 | → | -150 | → |
| 2015.03 | 2014/12/19 | 修正予 | 700 | ↓ | -170 | ↓ | -140 | ↓ | -150 | ↓ |
| 2015.03 | 2014/11/07 | Q2予 | 900 | → | 10 | → | 10 | → | 3 | → |
| 2015.03 | 2014/08/05 | Q1予 | 900 | → | 10 | → | 10 | → | 3 | → |
| 2015.03 | 2014/05/13 | 当初予 | 900 | - | 10 | - | 10 | - | 3 | - |
| 2014.03 | 2014/05/13 | 実 | 670 | → | -107 | → | -99 | → | -114 | → |
| 2014.03 | 2014/05/02 | 当初予 | 670 | - | -107 | - | -99 | - | -114 | - |
